Table 1 Clinical characteristics.
Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sex | M | M | F | M | M | F | M | M | F | F | F | M | M | M |
Age at diagnosis (yrs) | 32 | 23 | 37 | 21 | 14 | 15 | 13 | 37 | 17 | 14 | 32 | 20 | 25 | 26 |
Tissue source | Hepatic primary | Hepatic primary | Hepatic primary | Peritoneal metastasis | Hepatic primary, retroperitoneal lymph node metastasis | Hepatic primary | Hepatic primary, retroperitoneal lymph node metastasis | Hepatic recurrence | Hepatic primary, peritoneal metastases | Hepatic primary | Hepatic primary | Hepatic primary | Hepatic primary | Hepatic primary |
Age at surgery for tissue source | 32 | 23 | 37 | 27 | 14, 15 | 16 | 13, 16 | 63 | 18,21 | 14 | 32 | 20 | 26 | 26 |
Neoadjuvant therapy | None | None | None | Gemcitabine, oxaloplatin, and bevacizumab | None | Sorafenib, chemo-embolization with mitomycin, cisplatin, and adriamycin | None | None | None | None | None | None | None | None |
Initial resection tumor grade | 2 | 2 | 3 | N/A | N/A | N/A | 2 | N/A | 2 | 2 | 2 | 2 | 2 | N/A |
Initial resection tumor size (cm) | 5.5 | 10.5 | 8.0 | 11.0 | 11.0 | 20.0 | 9.5 | 13.0 | 9.5 | 10.5 | 5.0 | 12.0 | 14.7 | 11.0 |
Initial resection lymph nodes positive/total lymph nodes | N/A | 5/9 | 26/35 | N/A | 2/2 | 0/8 | 0/2 | 0/2 | 0/8 | 0/3 | 0/5 | 0/9 | 0/9 | 3/21 |
Initial resection smallest margin (cm) | 2.0 | 0.1 | 3.5 | 0.7 | 0.4 | Transplant | 0.2 | Unknown | Positive | 1.1 | 2.0 | 0.5 | 0.1 | 0.1 |
Adjuvant therapy | Additional resection, radiation, kinase inhibitor clinical trial | Gemcitabine and oxaloplatin, everolimus clinical trial, IFN-α and capecitabine | Additional resection and HIPEC, nivolumab | Additional resection × 7, panitimumab, erlotinib, IFN-α and capecitabine, radiation, lapitinib | Additional resection × 2, Sorafenib, Gemcitabine and Oxaloplatin | Liver transplant with initial resection, Cisplatin and Doxorubicin | Additional resection × 3, radiation | Additional resection × 3, RFA ablation, Cisplation and 5-FU, FOLFOX, radiation | Additional resection, DNAK-PKAc fusion peptide vaccine with Nivolumab and Ipilimumab, Lenvatinib | None | None | None | None | None |
Days from initial resection to recurrence | 508 | 176 | 404 | 300 | 59 | N/A | 669 | 8401 | 1346 | N/A | N/A | N/A | 384 | N/A |
Recurrence location | Liver, diaphragm | Liver, lung | Liver, peritoneum | Liver, retroperitoneal and mediastinal lymph nodes, peritoneum | Lung, mediastinum | None | Retroperitoneal lymph nodes, lung | Liver, mediastinal lymph nodes, chest wall | Pelvis, peritoneum | N/A | N/A | N/A | Liver | N/A |
Days from initial resection until death or last clinical encounter (*currently alive) | 1013 | 671 | 1345 | 2248 | 669 | 4691* | 3852* | 943 | 1840* | 1389* | 445* | 48* | 392* | 68* |
